Biogen wins MS drug approval in Europe; Cancer-drug sales help Celgene beat on profit;

@FiercePharma: Top-read in FP Weds: News flash for biopharma bosses: More than half your employees want to leave. Story | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: 3-D manufacturing being used in medical devices. When will pharma benefit? FierceMedicalDevices feature | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline's the No. 3 vaccines maker now, but its Novartis assets may change that picture. More | Follow @CarlyHFierce

> The EU has green-lighted Biogen Idec's ($BIIB) new multiple sclerosis therapy, Plegridy. Release

> Celgene ($CELG) profits topped analyst estimates thanks to higher sales of its cancer drugs. Report

> The FDA has approved Eagle Pharmaceuticals' ($EGRX) Ryanodex for the treatment of malignant hyperthermia. Release

> GlaxoSmithKline ($GSK) has seen "very significant" interest in its portfolio of older drugs, CEO Andrew Witty says. Report

> The FDA has accepted an application from Novartis' ($NVS) Sandoz unit for a biosimilar of Amgen's ($AMGN) Neopogen. Release

> Lawyers who battled Pfizer ($PFE) over women's cancers linked to the company's Prempro menopause drug settled a public dispute over $62 million in fees. Report

> Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight, the EMA says. Release

> Slovenia's Krka says its first-half group net profit is up 6%. Report

Medical Device News

@FierceMedDev: Nanoparticles point to cancerous tumors in MRIs. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Sofinnova closes $500M venture fund, keeps late-stage focus. Article | Follow @StacyALawrence

@VarunSaxena2: Frieden: "What works for Ebola is old fashioned public health." Says developing vaccine is difficult. | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: The top 5 vaccine makers brought in 86% of all vaccine sales in 2013. Find out who made the list here. Feature | Follow @EmilyWFierce

> Zimmer reports solid Q2 sales gains but lowers full-year estimates. News

> Nanoparticles point to cancerous tumors in MRIs. Story

> Augmenix aims for profitability with $10.8M Series D round as Varian acquisition option expires. More

Biotech News

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: Purdue earns a nod--and a quick slap--for abuse-resistant painkiller. News | Follow @JohnCFierce

@DamianFierce: $GILD's idelalisib will carry a boxed warning over serious liver toxicities. Here's the FDA's announcement. Release | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline steps closer to making world's first malaria vaccine. More from The Telegraph | Follow @EmilyMFierce

> FDA opens the door for a Novartis biosimilar of Amgen's Neupogen. Report

> A new VC player debuts with global plans to invest $150M in biotech startups. Article

> Israel's Atox banks $23M to fight flesh-eating bacteria. Story

Vaccines News

> Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo. More

> SEC charges CytoGenix CEO, 'serial con artist' with fraud. News

> Sinovac nabs Chinese vaccine tenders for hep A, influenza. Item

> GSK submits world's first malaria vaccine for EMA approval. Story

> Fluviral, FluLaval Tetra production on hold at Glaxo's troubled Quebec plant. Article

Pharma Manufacturing News

> Out with the new and in with the old after GSK trips up at vaccine plant. Story

> AmerisourceBergen deal with Walgreen reaps rewards, and costs. More

> FDA warns hospitals that Texas compounder's products are unsafe. Article

> Indian API maker voluntarily halts shipments to the U.S. Story

> Feds extract guilty plea from Turkish man accused of smuggling counterfeit Avastin. Report

And Finally... Japan will provide expertise to speed up Brazil's ability to assess the safety of new drugs. More